Similar antiviral efficacy and tolerability between efavirenz and lopinavir/ritonavir, administered with abacavir/lamivudine (Kivexa®), in antiretroviral-naïve patients: A 48-week, multicentre, randomized study (Lake Study)

Antiviral Research

Volumn 85, Issue 2, 2010, Pages 403-408

  Echeverria P ^a   Negredo, E ^a   Carosi, G ^b   Galvez J ^c   Gomez J L ^d   Ocampo, A ^e   Portilla, J ^f   Prieto, A ^g   Lopez J C ^h   Rubio, R ⁱ   Marino A ^j   Pedrol, E ^k   Vilades C ^l   del Arco, A ^m   Moreno, A ⁿ   Bravo, I ^a   Lopez Blazquez R ^a   Perez Alvarez N ^a,o   Clotet, B ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b Hospital de Brescia   (Italy)

^c HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^d HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^e HOSPITAL XERAL CALDE   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^g Instituto de Salud Carlos III   (Spain)

^h HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

ⁱ HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^j Universidad de La Coruña   (Spain)

^k HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^l HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^m HOSPITAL COSTA DEL SOL   (Spain)

ⁿ HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^o UNIVERSITAT POLITÈCNICA DE CATALUNYA   (Spain)

more..

Author keywords

Efavirenz; Efficacy; Kivexa ; Lopinavir ritonavir; Randomized study; Tolerability

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; EFAVIRENZ; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HLA B ANTIGEN; LOPINAVIR PLUS RITONAVIR; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; CD4 LYMPHOCYTE COUNT; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; FEMALE; HIV INFECTIONS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD; WITHHOLDING TREATMENT;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 74449087656     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2009.11.008     Document Type: Article

References (19)

1. Allavena C., Ferré V., Brunet-François C., Delfraissy J.F., Lafeuillade A., Valantin M.A., et al. Efficacy and tolerability of a nucleoside reverse transcriptase inhibitor-sparing combination of lopinavir/ritonavir and efavirenz in HIV-1-infected patients. Acquir. Immune Defic. Syndr. 39 (2005) 300-306
2. Arribas J.R., Pulido F., Miró J.M., Costa M., González J., Rubio R., et al. High effectiveness of efavirenz based highly active antiretroviral therapy in HIV-1-infected patients with fewer than 100 CD4 cells/microliter and opportunistic diseases: the EfaVIP study (efavirenz in very immunosuppressed patients). AIDS 16 (2002) 1554-1556
3. Bartlett J.A., DeMasi R., Quinn J., Moxham C., and Rousseau F. Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS 15 (2001) 1369-1377
4. Bartlett J., Chen S.-S., and Quinn J.B. Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. HIV Clin. Trials 8 (2007) 221-226
5. De luca A., Cozzi-Lepri A., Antinori A., Zaccarelli M., Bongiovanni M., Di Giambenedetto S., et al. Lopinavir/ritonavir or efavirenz plus two nucleoside analogues as first-line antiretroviral therapy: a non-randomized comparison. Antivir. Ther. 11 (2006) 609-618
6. Domingo P., Suárez-Lozano I., Torres F., Teira R., Lopez-Aldeguer J., Vidal F., et al. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J. Antimicrob. Chemother. 61 6 (2008) 1348-1358 Jun
7. Dubé M.P., Parker R.A., Tebas P., Grinspoon S., Zackin R., Robbins G., et al. Glucosa metabolism, lipid and body fat changes in ARV-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 19 (2005) 1807-1818
8. EACS Guidelines for the clinical management and treatment of HIV infected adults in Europe. Available at http://www.eacs.eu/guide/index.htm. Last accessed 14 March 2009.
9. Friedl A., Ledergerber B., Flepp M., Hirschel B., Telenti A., Furrer H., et al. Response to first protease inhibitor-and-efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS 15 (2001) 1793-1800
10. Mallal S., Nolan D., Witt C., Masel G., Martin A.M., Moore C., et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse transcriptase inhibitor abacavir. Lancet 359 (2002) 727-732
11. Mallal S., Phillips E., Carosi G., Molina J.M., Workman C., Tomazic J., et al., PREDICT-1 Study Team. HLA-B*5701 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358 (2008) 568-579
12. Manfredi R., Calza L., and Chiodo F. Fist-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 18 (2004) 2331-2333
13. Molina, J.M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., et al. Efficacy and safety of once-daily atazanavir/ritonavir compared to twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabinein ARV-naive HIV-1-infected subjects: the CASTLE study, 48-week results. In: 15th Conference on Retroviruses and Opportunistic Infections, 2008. (Abstract 37).
14. Negredo E., Ribalta J., Ferré R., Salazar J., Rey-Joli C., Sirera G., et al. Efavirenz induces a striking and generalized increase of HDL cholesterol in HIV infected patients. AIDS 18 (2004) 819-821
15. Phillips E., Wong G., Kaul R., Shahabi K., Nolan D., Knowles S., et al. Clinical and inmunogenetic correlates of abacavir hypersensitivy. AIDS 19 (2005) 979-987
16. Pulido F., Arribas J., Miró J., Costa M., González J., Rubio R., et al. Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study). J. Acquir. Immune Defic. Syndr. 35 (2004) 343-350
17. Riddler S., Haubrich R., DiRienzo G., Peeples L., Powderly W., Klingman K., et al. Class-sparing regimens for initial treatment of HIV-1 infection. N. Engl. J. Med. 358 15 (2008) 2095-2106
18. Tashima K., Staszewski S., Nelson M., Rachlis A., Skiest D., Stryker R., et al. Efficacy and tolerability of long-term efavirenz plus nucleoside reverse transcriptase inhibitors for HIV-1 infection. AIDS 22 (2008) 275-279
19. Torti C., Maggiolo F., Patroni A., Suter F., Ladisa N., Paraninfo G., et al. Exploratory analysis for the evaluation of lopinavir/ritonavir versus efavirenz-based HAART regimens in antiretroviral-naive HIV-positive patients: results from the Italian MASTER Cohort. J. Antimicrob. Chemother. 56 (2005) 190-195